LAUSR

Gilead Buys into Tizona's Anti-HLA-G Strategy.

Sign Up to like & get
recommendations!
1 Published in 2020 at "Cancer discovery"

DOI: 10.1158/2159-8290.cd-nb2020-077

Abstract: Gilead announced plans in July to pay $300 million for a 49.9% stake in Tizona Therapeutics, with the option to buy the rest of the company for $1.25 billion. Whether Gilead follows through with the… read more here.

Keywords: buys tizona; gilead; gilead buys; hla strategy ... See more keywords